focus -WSS

focus

author：leisure time 2025-09-28 00:49:21 - browse：15523

There are a lot of reasons why updated data on Pfizer’s Lorbrena, a treatment for non-small cell lung cancer, might not seem to be a big deal. The results are an update on the clinical trial that resulted in the Food and Drug Administration granting Lorbrena full approval in 2001, so in a sense they are not even that new. For Pfizer investors, Lorbrena isn’t that big a deal, either. The medicine, for patients whose lung tumors have particular genetic mutations, generated only $575 million last year — an amount that is up 57% from the year prior, but that still constitutes only 1% of the drug giant’s annual sales.

But there is one number that makes the Lorbrena data quite eye-catching: In the updated data, the daily pill decreased the risk that cancer would progress or that a patient would die by 81% over five years.

That’s a stunning number, especially when one considers that Lorbrena was not being compared to an inert placebo but to Xalkori, another Pfizer targeted cancer drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Medicare drug price negotiation legal challenge met with skepticism

explore

WSS

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

5 takeaways from STAT's examination of Zynex Medical

Report captures long Covid’s disabling effects and policy challenges

The Affordable Care Act has saved billions in health care costs

Medicare Advantage insurers face 0.2% cut to 2025 payments

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

focus

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Merck, Johnson & Johnson CEOs will testify on high drug prices

In age of alternative facts, a scholarly course on calling out crap

FTC sues over Novant Health acquisition of two N.C. hospitals

Hepatitis C has a cure — but many Americans still lack access to it

Readers discuss the intersection of pregnancy and addiction

As demand for Covid shots wanes, Moderna seeks its next success

Pancreatic cancer early detection could be helped by AI

ChatGPT in medicine: STAT answers readers' burning questions

Biogen walks away from Aduhelm, years after polarizing approval

hotspot

Pancreatic cancer early detection could be helped by AI

How generative AI ratchets up security threats for health systems

Medical device trials still don't enroll enough women, study finds

Venture capital firm's plans to take over Akron hospital face hurdles

How generative AI ratchets up security threats for health systems

Why Medicare shouldn’t cover every FDA

knowledge

explore

explore

explore